BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26255764)

  • 1. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma.
    Lyhne NM; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Evensen J; Mortensen HR; Overgaard J
    Radiother Oncol; 2015 Oct; 117(1):91-8. PubMed ID: 26255764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer.
    Mortensen HR; Overgaard J; Specht L; Overgaard M; Johansen J; Evensen JF; Andersen LJ; Andersen E; Grau C
    Radiother Oncol; 2012 Apr; 103(1):69-75. PubMed ID: 22398313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.
    Lassen P; Eriksen JG; Krogdahl A; Therkildsen MH; Ulhøi BP; Overgaard M; Specht L; Andersen E; Johansen J; Andersen LJ; Grau C; Overgaard J;
    Radiother Oncol; 2011 Jul; 100(1):49-55. PubMed ID: 21429609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
    Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
    Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study.
    Moon SH; Cho KH; Chung EJ; Lee CG; Lee KC; Chai GY; Kang KM; Lee JY; Chung WK; Park WY; Kim JH
    Radiother Oncol; 2014 Jan; 110(1):98-103. PubMed ID: 24161568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated radiotherapy for T1 to T2 glottic cancer.
    Motegi A; Kawashima M; Arahira S; Zenda S; Toshima M; Onozawa M; Hayashi R; Akimoto T
    Head Neck; 2015 Apr; 37(4):579-84. PubMed ID: 24677592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
    Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of and survival after glottic squamous cell carcinoma in Denmark from 1971 to 2011-A report from the Danish Head and Neck Cancer Group.
    Lyhne NM; Johansen J; Kristensen CA; Andersen E; Primdahl H; Andersen LJ; Oksbjerg S; Overgaard J
    Eur J Cancer; 2016 May; 59():46-56. PubMed ID: 27014799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
    Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
    Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group.
    Lyhne NM; Johansen J; Kristensen CA; Andersen E; Primdahl H; Andersen LJ; Bøje CR; Jensen AR; Overgaard J
    Radiother Oncol; 2016 Feb; 118(2):257-66. PubMed ID: 26897514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
    Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
    Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected radiation laryngeal necrosis after carbon ion therapy using conventional dose fractionation for laryngeal cancer.
    Demizu Y; Fujii O; Nagano F; Terashima K; Jin D; Mima M; Oda N; Takeuchi K; Takeda M; Ito K; Fuwa N; Okimoto T
    Jpn J Clin Oncol; 2015 Nov; 45(11):1076-81. PubMed ID: 26355161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.
    Overgaard J; Mohanti BK; Begum N; Ali R; Agarwal JP; Kuddu M; Bhasker S; Tatsuzaki H; Grau C
    Lancet Oncol; 2010 Jun; 11(6):553-60. PubMed ID: 20382075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer.
    Mortensen HR; Overgaard J; Jensen K; Specht L; Overgaard M; Johansen J; Evensen JF; Andersen E; Andersen LJ; Hansen HS; Grau C;
    Acta Oncol; 2013 Oct; 52(7):1535-42. PubMed ID: 24047339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of insulin-like growth factor-1 receptor for predicting early glottic carcinoma response to radiotherapy.
    Matsumoto F; Ohba S; Fujimaki M; Ikeda K
    Auris Nasus Larynx; 2016 Aug; 43(4):440-5. PubMed ID: 26739949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis.
    Matuschek C; Haussmann J; Bölke E; Gripp S; Schuler PJ; Tamaskovics B; Gerber PA; Djiepmo-Njanang FJ; Kammers K; Plettenberg C; Anooshahr B; Orth K; Budach W
    Radiat Oncol; 2018 Oct; 13(1):195. PubMed ID: 30286777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early glottic carcinoma treated by radiotherapy: defining a population for surgical salvage.
    Smee RI; Williams JR; Broadley K; Bridger GP
    Laryngoscope; 2013 Jan; 123(1):171-6. PubMed ID: 23007323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of stage IV glottic carcinoma: therapeutic outcomes.
    Spector GJ; Sessions DG; Lenox J; Newland D; Simpson J; Haughey BH
    Laryngoscope; 2004 Aug; 114(8):1438-46. PubMed ID: 15280724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.